192 related articles for article (PubMed ID: 28124080)
1. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab.
Alashkar F; Vance C; Herich-Terhürne D; Preising N; Dührsen U; Röth A
Ann Hematol; 2017 Apr; 96(4):589-596. PubMed ID: 28124080
[TBL] [Abstract][Full Text] [Related]
2. A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab.
Reher D; Fuhrmann V; Kluge S; Nierhaus A
Vaccine; 2018 May; 36(19):2507-2509. PubMed ID: 29631884
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.
Bozio CH; Isenhour C; McNamara LA
PLoS One; 2020; 15(11):e0241989. PubMed ID: 33180804
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients.
Langereis JD; van den Broek B; Franssen S; Joosten I; Blijlevens NMA; de Jonge MI; Langemeijer S
Blood Adv; 2020 Aug; 4(15):3615-3620. PubMed ID: 32766853
[TBL] [Abstract][Full Text] [Related]
5. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab.
Gäckler A; Kaulfuß M; Rohn H; Vogel U; Claus H; Feldkamp T; Kribben A; Witzke O
Nephrol Dial Transplant; 2020 Feb; 35(2):298-303. PubMed ID: 29992261
[TBL] [Abstract][Full Text] [Related]
6. Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition.
Alashkar F; Vance C; Herich-Terhürne D; Turki AT; Schmitz C; Bommer M; Hüttmann A; Dührsen U; Vogel U; Röth A
Vaccine; 2019 Oct; 37(44):6682-6687. PubMed ID: 31562002
[TBL] [Abstract][Full Text] [Related]
7. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.
Borrow R; Andrews N; Goldblatt D; Miller E
Infect Immun; 2001 Mar; 69(3):1568-73. PubMed ID: 11179328
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab in paroxysmal nocturnal haemoglobinuria.
Charneski L; Patel PN
Drugs; 2008; 68(10):1341-6. PubMed ID: 18578555
[TBL] [Abstract][Full Text] [Related]
10. [Management of paroxysmal nocturnal hemoglobinuria: an update].
Kawaguchi T
Rinsho Ketsueki; 2018; 59(6):703-710. PubMed ID: 29973448
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.
Zareba KM
Drugs Today (Barc); 2007 Aug; 43(8):539-46. PubMed ID: 17925885
[TBL] [Abstract][Full Text] [Related]
12. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
13. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.
McNamara LA; Topaz N; Wang X; Hariri S; Fox L; MacNeil JR
MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):734-737. PubMed ID: 28704351
[TBL] [Abstract][Full Text] [Related]
14. Immune responses following meningococcal serogroups A, C, Y and W polysaccharide vaccination in C2-deficient persons: evidence for increased levels of serum bactericidal antibodies.
Brodszki N; Skattum L; Bai X; Findlow H; Borrow R; Jönsson G
Vaccine; 2015 Apr; 33(15):1839-45. PubMed ID: 25707694
[TBL] [Abstract][Full Text] [Related]
15. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Dmytrijuk A; Robie-Suh K; Cohen MH; Rieves D; Weiss K; Pazdur R
Oncologist; 2008 Sep; 13(9):993-1000. PubMed ID: 18784156
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.
Konar M; Granoff DM
Blood; 2017 Aug; 130(7):891-899. PubMed ID: 28630122
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
[TBL] [Abstract][Full Text] [Related]
18. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
19. Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome.
Mülling N; Rohn H; Vogel U; Claus H; Wilde B; Eisenberger U; Kribben A; Witzke O; Gäckler A
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32159209
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.
MacNeil JR; Rubin LG; Patton M; Ortega-Sanchez IR; Martin SW
MMWR Morb Mortal Wkly Rep; 2016 Nov; 65(43):1189-1194. PubMed ID: 27811836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
